Pangaea Data Expands its AI Platform to Support Decision-Making & Guideline-Concordance for MDT Tumor Boards Across Enterprise & Community Care 

London, UK and South San Francisco, CA, USA, 27th May 2026: Pangaea Data (Pangaea) has today announced it is expanding the capabilities of its guideline-configured AI platform to support Multidisciplinary Team (MDT) Tumor boards, bringing automated guideline concordance review, clinical trial matching and workflow optimization directly into decision-making processes for cancer patients.

More than 80% of oncology patients in the United States are treated in community-based practices, where clinicians often face significant resource and staffing constraints. At the same time, MDT preparation can require more than two hours per clinician each week, adding substantial administrative burden to already stretched oncology teams. As precision oncology continues to evolve rapidly, MDTs are under growing pressure from increasing patient volumes, fragmented clinical records, expanding biomarker-driven therapies, and increasingly complex treatment guidelines. Ensuring that every patient is evaluated against the full range of available testing, treatment, and clinical trial opportunities has become increasingly time-consuming and difficult, particularly in community practice settings. As a result, major gaps in cancer care persist, with an estimated 80–90% of eligible patients being missed for precision therapies or clinical trials.

Pangaea’s platform is designed to address these challenges and streamline MDT workflows—from preparation and the MDT meeting itself to follow-up activities—without requiring clinicians and healthcare providers to pre-empt and rely on predefined prompts.

The first aspect of this capability is continuous guideline concordance and trial matching. The platform automatically evaluates longitudinal patient records against configured clinical guidelines and trial criteria to identify where patients may be eligible for screening, biomarker testing, targeted therapies, or clinical trials, without requiring clinicians to manually query or prompt the system, which can be particularly challenging when addressing care gaps that are effectively “unknown unknowns.” By proactively surfacing these insights directly within the electronic health record (EHR) and existing communication tools, the platform is designed to help clinicians identify care opportunities that might otherwise be missed within increasingly complex clinical workflows.

Pangaea found that only 47% of metastatic breast cancer (mBC) patients were tested for all clinically indicated genomic biomarkers, and of those, just 7.4% received testing early enough to inform treatment decisions (identified with 100% accuracy). Among patients who did receive timely and concordant testing, 58% had first-line treatment that deviated from guidelines (identified with 97.4% accuracy) and 36% had second-line treatment that deviated from guidelines (identified with 100% accuracy).

Separately, in a study conducted with NHS Lothian, which is being presented at ASCO Annual Meeting 2026, Pangaea’s platform achieved significantly higher precision in identifying cancer cachexia patients (who were hidden in plain sight), compared to ICD-code approaches, traditional Natural Language Processing (NLP) methods and generalized large language models (LLMs).

These findings highlight the advantages of configuring AI models directly against established clinical guidelines and care pathways, rather than relying solely on generalized or prompting-based LLMs.

The second aspect of Pangaea’s capabilities to improve efficiency of MDT workflows is around automatic consolidation of fragmented patient records, generating structured patient summaries, referral documentation, and MDT checklists, while simultaneously evaluating the EHRs against current treatment guidelines and clinical trial criteria.

By reducing the administrative burden associated with MDT preparation and standardizing how cases are reviewed, the platform is designed to help healthcare organizations increase MDT capacity, improve workflow efficiency, and enable specialist teams to focus more time on complex clinical decision-making to achieve optimal patient outcomes. the best outcomes for the patients.

“Healthcare systems are under enormous pressure to deliver increasingly personalized cancer care while managing rising clinical workloads,” said Vibhor Gupta, PhD, CEO & Founder of Pangaea Data. “Our goal is to help clinicians identify the right patients at the right time while reducing the operational friction that often delays access to specialist review, precision therapies, and clinical trials. We believe guideline-configured AI can help make precision oncology more proactive, scalable, and equitable across healthcare systems.”

Pangaea is expanding access to its platform across both major cancer centers and community-practices through a range of deployment models, including enterprise integrations, APIs, and lighter-weight access options that do not require dedicated technical infrastructure. The approach is intended to help extend access to advanced oncology decision-support capabilities and MDTs beyond major academic centers and into lower-resource healthcare environments globally.

The company is deploying these MDT-focused capabilities across the United States (USA), United Kingdom (UK), Europe, Middle East, Latin American (LATAM) and Asia Pacific (APAC) markets.

“Pangaea Data’s expansion into the USA, Europe, Middle East, LATAM and APAC markets is a prime example of the pioneering British innovation we are proud to champion this month at Greater Together Los Angeles,” said Blair McDougall, MP, UK Minister for Small Business and Economic Transformation. “By helping healthcare systems operationalize precision medicine more effectively through AI, this trailblazing company is not only driving transatlantic economic growth but also strengthening the UK’s position as a global leader in life sciences and precision healthcare.”

As oncology care becomes increasingly personalized and operationally complex, healthcare systems face growing pressure to deliver timely and equitable access to evidence-based treatment pathways. Through its expanded MDT capabilities and guideline-configured AI platform, Pangaea aims to help healthcare organizations scale precision oncology while reducing operational burden and improving patient access to appropriate testing, therapies, and clinical trials.

-ENDS – 

Contact: pr@pangaeadata.ai